Doximity’s stock skyrockets 50% on medical AI excitement. Can the rally last?
1 min read
The story
Doximity’s stock has skyrocketed 50% as investors focus on the company’s potential in medical AI. The headline presents that opportunity alongside a direct concern: new AI products could cannibalize Doximity’s established medical-networking business.
The company generated $644.9M of revenue in the fiscal year ended March 31, 2026, up 13.1% year over year. It also reported an 89.1% gross margin, a 30.4% net margin and $0.98 of diluted EPS, giving the bull case a profitable base from which to fund or scale AI products.
The key tension is whether AI becomes an incremental growth engine or changes the economics of the existing franchise. A 50% share-price surge raises the importance of evidence on adoption, monetization and any impact on the core business, but the supplied information does not include valuation, analyst targets or management guidance.
The next read-throughs are AI revenue or usage disclosures, evidence of cross-selling into Doximity’s physician network, and signs that the core networking business is holding up. Until those data points arrive, the strong financial profile and the cannibalization concern support competing cases rather than a clear directional conclusion.
The case — both sides
DOCS’s $644.9M revenue base, 13.1% year-over-year growth and 30.4% net margin provide financial support for an AI product that could expand the platform rather than merely repackage existing activity.
The 50% rally may be vulnerable if medical AI substitutes for the core networking business, while the available data offers no evidence yet that AI revenue or adoption is incremental.
The house read
Two-sidedDOCS investors are weighing whether medical AI can add to a profitable networking platform or erode the core business after the stock’s 50% surge.
Wrong ifThe setup resolves against this neutral view if management provides clear evidence of accelerating AI monetization without weakening the core medical-networking business, or if disclosures show meaningful cannibalization.
Published read · research, not advice